Skip to main content
SpringerLink
Log in

Parkinsonism-Hyperpyrexia Syndrome in Parkinson’s Disease

  • Chapter
Movement Disorder Emergencies

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

A 44-year-old right-handed man with a 14-year history of Parkinson’s disease (PD) presented to the emergency department with an acute onset of fever, confusion, rapidly progressive difficulty with ambulation, and dysphagia. He presented initially in 1987 with left upper limb tremor and slowness. Work-up for secondary parkinsonism was unrevealing, and treatment was initiated first with anticholinergic agents and then levodopa. By 1991, he had developed bilateral symptoms and signs. Motor fluctuations and complications emerged within 5 years of onset, with considerable anxiety and behavioral problems as well. He required high doses of dopaminergic agents for the last 8 years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Delay J, Pichot P, Lemperiere T, et al. Un neuroleptique majeur non-phenothiazinique et non-reserpinique, l’haloperiol, dans le traitment des psychosis. Annales Medicopsychologiques 1960;118:145–142.

    Google Scholar 

  2. Delay J, Denicker P. Drug induced extrapyramidal syndromes. In: Vinken PJ, Bruyun GW, eds. Handbook of Clinical Neurology Amsterdam, North Holland: 1968;258–259.

    Google Scholar 

  3. Factor SA, Singer C. Neuroleptic malignant syndrome. In: Lang AE and Weiner WJ, eds. Drug-induced Movement Disorders. Futura, Mount Kisco, NY: 1992;199–230.

    Google Scholar 

  4. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79–82.

    PubMed  CAS  Google Scholar 

  5. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986;73:337–347.

    Article  PubMed  CAS  Google Scholar 

  6. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989;146:717–725.

    PubMed  CAS  Google Scholar 

  7. Kurlan R, Hamill R, Shoulson I. Neuroleptic malignant syndrome. Clin Neuropharmacol 1984;7:109–120.

    Article  PubMed  CAS  Google Scholar 

  8. Mueller PS. Diagnosis and treatment of neuroleptic malignant syndrome: a review. Neuroview 1987;3:1–5.

    Google Scholar 

  9. Burke RE, Fahn S, Mayuex R, et al. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington’s disease. Neurology 1981;31:1022–1026.

    PubMed  CAS  Google Scholar 

  10. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705–713.

    PubMed  CAS  Google Scholar 

  11. Kosten TR, Kleber HD. Rapid death during cocaine abuse: a variant of neuroleptic malignant syndrome. Am J Drug Alcohol Ab 1988;14:335–346.

    Article  CAS  Google Scholar 

  12. Toro M, Matsuda O, Mikizuich K, Sugano K. Neuroleptic malignant syndrome-like state following withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 1981;169:324–327.

    Article  Google Scholar 

  13. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant like syndrome due to levodopa therapy withdrawal. JAMA 1985;254:2792–2795.

    Article  PubMed  CAS  Google Scholar 

  14. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson’s disease. Mov Disord 2001;16:960–961.

    Article  PubMed  CAS  Google Scholar 

  15. Pfeiffer RF, Sucha EL. “On-off“-induced lethal hyperthermia. Mov Disord 1989;4:338–341.

    Article  PubMed  CAS  Google Scholar 

  16. Serrano-Duenos M. Neuroleptic malignant syndrome-like, or—dopaminergic malignant syndrome—due to levodopa therapy withdrawal, clinical features in 11 patients. Parkinsonism Relat Dis 2003;9:175–178.

    Article  Google Scholar 

  17. Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in Parkinson’s disease after withdrawal of alteration of dopaminergic therapy. Arch Int Med 1991;151:794–796.

    Article  CAS  Google Scholar 

  18. Sechi GP, Tanda F, Mutani R. Fatal hyperpyrexia after withdrawal of levodopa. Neurology 1984;34:249–251.

    PubMed  CAS  Google Scholar 

  19. Figá-Talamanca L, Gualandi C, DiMeo L, et al. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology 1985;35:258–261.

    PubMed  Google Scholar 

  20. Hirschorn KA, Greenberg HS. Successful treatment of levodopa induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome: a case report. Clin Neuropharmacol 1988;11:278–281.

    Article  PubMed  CAS  Google Scholar 

  21. Mayeux R, Stern Y, Mulvey K, et al. Reappraisal of temporary levodopa withdrawal (“drug holiday”) in Parkinson’s disease. N Engl J Med 1985;313:724–728.

    Article  PubMed  CAS  Google Scholar 

  22. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s Disease: drug-induced psychiatric states. Adv Neurol 1995;65:115–138.

    PubMed  CAS  Google Scholar 

  23. Iwuagwa CU, Riley D, Bonomo RA. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a catechol-o-methyltransferase inhibitor. Am J Med 2000;108:517–518.

    Article  Google Scholar 

  24. Cunningham MA, Darby DG, Donnan GA. Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity and autonomic dysfunction. Neurology 1991;41:942–943.

    PubMed  CAS  Google Scholar 

  25. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockage? Neurology 1981;31:132–137.

    PubMed  CAS  Google Scholar 

  26. Mizuta E, Yamasaki S, Nakatake M, Kuno S. Neuroleptic malignant syndrome in a Parkinsonian woman during the premenstrual period. Neurology 1993;43:1048–1049.

    PubMed  CAS  Google Scholar 

  27. Cao L, Katz RH. Acute hypernatremia and neuroleptic malignant syndrome in Parkinson disease. Am J Med Sci 1999;318:67–68.

    Article  PubMed  CAS  Google Scholar 

  28. The Deep Brain Stimulation For Parkinson’s Disease Study Group. Deep-Brain Stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med 2001;345:956–963.

    Article  Google Scholar 

  29. Vingerhoets FJG, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson’s disease: two-year follow-up. Neurology 2002;58:396–401.

    PubMed  Google Scholar 

  30. Kleiner-Fisman G, Saint-Cyr JA, Miyasaki J, Lozano A, Lang AE. Subthalamic DBS replaces levodopa in Parkinson’s disease (letter). Neurology 2002;59:1293–1294.

    PubMed  CAS  Google Scholar 

  31. Sato Y, Asoh T, Metoki N, Satoh K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:574–576.

    Article  PubMed  CAS  Google Scholar 

  32. Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease. Neurology 1999;52:777–781.

    PubMed  CAS  Google Scholar 

  33. Ueda M, Hamamoto M, Nagayama H, Okubo S, Amemiya S, Katayama Y. Biochemical alterations during medication withdrawal in Parkinson’s disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry 2001;71:111–113.

    Article  PubMed  CAS  Google Scholar 

  34. Kuno S, Komure O, Mizuta, Yamazaki S, Nishitani H. Neuroleptic malignant syndrome associated with withdrawal of antiparkinsonian drugs. In: Nagatsu T, Fisher A, Yoshida M, eds. Basic clinical and therapeutic aspects of Alzheimer’s and Parkinson’s disease, vol 2. Plenum, New York: 1990; 245–248.

    Google Scholar 

  35. Yamawaki Y, Ogawa N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson’s disease. Intern Med 1992;31:1298–1302.

    Article  PubMed  CAS  Google Scholar 

  36. Genis D. Neuroleptic malignant syndrome: impaired dopaminergic systems? Neurology 1985;35:1806.

    PubMed  CAS  Google Scholar 

  37. Konagaya M, Goto Y, Matsuoka Y. Neuroleptic malignant syndrome-like condition in multiple system atrophy. J Neurol Neurosurg Psychiatry 1997;63:120–121. Letter.

    Article  PubMed  CAS  Google Scholar 

  38. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000;15:201–211.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Movement Disorders Program, Department of Neurology, Emory University, Atlanta, GA

    Stewart A. Factor DO

  2. Rockwood Clinic, PS, Spokane, WA

    Anthony Santiago MD

Authors
  1. Stewart A. Factor DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony Santiago MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc.

About this chapter

Cite this chapter

Factor, S.A., Santiago, A. (2005). Parkinsonism-Hyperpyrexia Syndrome in Parkinson’s Disease. In: Movement Disorder Emergencies. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-902-8:029

Download citation

  • DOI: https://doi.org/10.1385/1-59259-902-8:029

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-305-3

  • Online ISBN: 978-1-59259-902-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation